LENZ Therapeutics' 15min chart triggers KDJ Death Cross, bearish Marubozu signal.

LENZ Therapeutics' 15-minute chart has recently triggered a KDJ Death Cross, accompanied by a Bearish Marubozu candlestick pattern at 08/29/2025 13:00. This indicates a shift in the momentum of the stock price towards the downside, with potential for further depreciation. The market is currently dominated by sellers, and the bearish momentum is likely to persist.

LENZ Therapeutics (LENZ) has recently encountered significant technical setbacks, with its 15-minute chart triggering a KDJ Death Cross and a Bearish Marubozu candlestick pattern on August 29, 2025, at 13:00. This combination of technical indicators suggests a shift in the stock's momentum towards the downside, potentially leading to further depreciation in the stock price [1].

The KDJ Death Cross, a bearish signal, indicates that the stock price is likely to continue its downward trend. The Bearish Marubozu candlestick pattern, characterized by a long lower wick and no upper wick, further supports this bearish sentiment. This pattern is typically seen when sellers are in control of the market, and the stock price is expected to decline [2].

Despite these negative technical signals, LENZ Therapeutics has recently received FDA approval for its aceclidine-based eye drop, LNZ100. This approval marks a significant milestone for the company, as it addresses presbyopia, the inevitable loss of near vision. The approval has lowered the risk of the investment and opened up new opportunities for the company, including partnerships with Lotus Pharmaceuticals and Laboratoires Théa for commercialization in various regions [1].

LENZ Therapeutics estimates a market size of $3B in the US alone, with a potential to capture 30% of this market. The company has a well-funded position, with over $200M in cash as of Q2 2025, providing a solid foundation for its growth plans. The company's sales team of over 100 members and direct-to-consumer strategies planned for Q1 2026 further support its growth prospects [1].

However, the technical indicators suggest a challenging period ahead. The MACD Death Cross and KDJ Death Cross are traditionally considered bearish signals, indicating a potential reversal in the stock's trend. Investors should closely monitor these indicators and consider the broader market conditions when making investment decisions [2].

References:
[1] https://www.marketscreener.com/news/lenz-therapeutics-corporate-presentation-ce7c50dfd98cf621
[2] https://seekingalpha.com/article/4817577-lenz-therapeutics-adjusting-my-position-after-almost-doubling-in-four-months